Ellie Leick

Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.

Prapti Patel, MD, discusses available and emerging treatment options for patients with acute myeloid leukemia.

Mira Hellmann, MD, discusses surgical and systemic advancements in the field of gynecologic oncology.

Sandy W. Wong, MD, discusses treatments in the pipeline for multiple myeloma.

Ruth O’Regan, MD, and Adam M. Brufsky, MD, PhD, FACP, both discuss the emergence of trastuzumab biosimilars in breast cancer.

Nancy U. Lin, MD, discusses research focusing on CNS penetration in HER2-positive metastatic breast cancer.

Erika P. Hamilton, MD, discusses research presented at the 2019 San Antonio Breast Cancer Symposium and how the data are impacting the treatment of patients with HER2-positive breast cancer.

Hope S. Rugo, MD, FASCO, discusses the updated findings of the SOPHIA trial in HER2-positive metastatic breast cancer.

Rashmi K. Murthy, MD, MBE, discusses the findings of the HER2CLIMB trial in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Martine J. Piccart, MD, PhD, discusses the 6-year follow-up of the APHINITY trial and its impact on the breast cancer field.

David F. McDermott, MD, discusses developments in the frontline setting for the treatment of patients with advanced renal cell carcinoma.

Alice Mims, MD, discusses biomarker research and therapeutic developments in acute myeloid leukemia.

Jennifer A. Woyach, MD, discusses the evolving treatment paradigm and sequencing challenges in chronic lymphocytic leukemia.

Maria Chaudhry, MBBS, discusses recent and ongoing research in newly diagnosed and relapsed/refractory multiple myeloma.

Ajjai Shivaram Alva, MBBS, highlights ongoing advances made in the treatment of patients with metastatic renal cell carcinoma.

Afonso Ribeiro, MD, discusses imaging modalities as well as challenges and future goals for the pancreatic cancer paradigm.

Nathan Pennell, MD, PhD, discusses the emerging widespread role of liquid biopsies in lung cancer and how to best utilize the approach in clinical practice.

Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.

Julie R. Gralow, MD, discusses the emergence of biosimilars in the United States and globally.

Brian A. Van Tine, MD, PhD, discusses the results of a phase I study looking at the effects of ADP-A2M4 in patients with synovial sarcoma.

Matthew P. Goetz, MD, discusses the current treatment landscape for patients with estrogen receptor-positive, HER2-negative breast cancer who harbor ESR1 mutations, and provided an overview of the ELAINE trial.

Casey M. Cosgrove, MD, discusses later-line treatments in ovarian cancer and ongoing research.

Rakesh Popat, MD, discusses the DREAMM-1 trial and how to manage the corneal adverse events that result from belantamab mafodotin treatment in patients with relapsed/refractory myeloma.

David F. Penson, MD, MPH, MMHC, discusses the current armamentarium and ongoing research in prostate cancer.

Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.

Mary J. Fidler, MD, discusses how recent research has impacted the EGFR-mutant non–small cell lung cancer landscape.

Raajit K. Rampal, MD, PhD, discusses current available treatments for patients with polycythemia vera and myelofibrosis, as well as the unmet needs in this area of research.

Investigators are exploring various treatment modalities in the multiple myeloma pipeline, many of them using BCMA as a target because of its high expression on myeloma cells.

Nina Shah, MD, discusses how CAR T-cell therapy, bispecific T-cell engagers, and antibody-drug conjugates are being used to treat patients with multiple myeloma.